Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).

ABSTRACT:

Objectives

To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.

Methods

The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months. AEs, including insomnia, falls, and cardiovascular events, were reported at every visit by participants and families using a symptom checklist.

Results

The study included 98 participants in the MPH group and 101 in the placebo group. Participants in the MPH group experienced g

SUBMITTER: Zeng L 

PROVIDER: S-EPMC11265565 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature